NCT00433537View on ClinicalTrials.gov

Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Contiguous Stage II Mantle Cell LymphomaNoncontiguous Stage II Mantle Cell LymphomaStage I Mantle Cell LymphomaStage III Mantle Cell LymphomaStage IV Mantle Cell Lymphoma
Interventions
DRUG

bortezomib

Given IV

BIOLOGICAL

rituximab

Given IV

DRUG

cyclophosphamide

Given IV

DRUG

doxorubicin hydrochloride

Given IV

DRUG

vincristine

Given IV

DRUG

dexamethasone

Given IV

BIOLOGICAL

filgrastim

Given SC

BIOLOGICAL

pegfilgrastim

Given SC

PROCEDURE

Autologous stem cell transplantation (ASCT)

Trial Locations (1)

02215

Eastern Cooperative Oncology Group, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00433537 - Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma | Biotech Hunter | Biotech Hunter